For the second quarter of 2025, Gilead (GILD) currently expects $61M in acquired IPR&D expenses, representing a charge of roughly 4c to both GAAP and non-GAAP earnings per share. Acquired IPR&D expenses could include in any given quarter known commitments associated with previously announced collaborations and partnerships and upfront and other expenses associated with newly announced business development activities that took place in the quarter. The second quarter of 2025 acquired IPR&D expenses include: roughly $40M associated with its strategic partnership with Kymera (KYMR); roughly $21M related to other collaborations and partnerships.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead Sciences’ Phase 3 Study: A New Hope for HIV-1 Treatment?
- Gilead Sciences Advances HIV Prevention with Lenacapavir Study
- Gilead Sciences’ New HIV Treatment Study: A Potential Game Changer?
- Gilead to supply lenacapavir to Global Fund for up to 2M people
- Positive Outlook for Gilead Sciences Driven by Yeztugo’s Market Potential and FDA Approval